Unplanned admissions for patients with myeloma in the UK: Low frequency but high costs.

Costs Elective admissions Multiple myeloma Unplanned admissions

Journal

Journal of bone oncology
ISSN: 2212-1366
Titre abrégé: J Bone Oncol
Pays: Netherlands
ID NLM: 101610292

Informations de publication

Date de publication:
Aug 2019
Historique:
received: 15 03 2019
revised: 31 05 2019
accepted: 04 06 2019
entrez: 22 6 2019
pubmed: 22 6 2019
medline: 22 6 2019
Statut: epublish

Résumé

Multiple myeloma (MM) is associated with high healthcare resource utilisation and increasing hospitalisation rates. The aim of this study was to characterise the hospital use by patients with MM in the English National Health Service (NHS). Routinely-collected aggregate data about all NHS-funded hospital admissions of patients with MM were analysed. Data were obtained from the English Hospital Episodes Statistics on admissions between 1 April 2014 and 31 March 2018. A total of 754,345 admissions were reported over four years, equivalent to a mean of 188,586 admissions per year. Of the 41,845 patients admitted during this period, 42% were women and 58% men. From the total admissions, 90% were elective and 10% unplanned. Mean annual estimated costs over the period were £46 million for elective and £56 million for unplanned admissions. The number of elective admissions increased by 4.5% with costs increasing 1.5% per year; for unplanned admissions, these figures were 4.1% and 9.0%, respectively. MM is associated with a significant number of hospital admissions and NHS costs. The majority of the hospital admissions are elective, but the highest burden in terms of costs relates to unplanned admissions, with numbers increasing over time.

Sections du résumé

BACKGROUND BACKGROUND
Multiple myeloma (MM) is associated with high healthcare resource utilisation and increasing hospitalisation rates. The aim of this study was to characterise the hospital use by patients with MM in the English National Health Service (NHS).
METHODS METHODS
Routinely-collected aggregate data about all NHS-funded hospital admissions of patients with MM were analysed. Data were obtained from the English Hospital Episodes Statistics on admissions between 1 April 2014 and 31 March 2018.
RESULTS RESULTS
A total of 754,345 admissions were reported over four years, equivalent to a mean of 188,586 admissions per year. Of the 41,845 patients admitted during this period, 42% were women and 58% men. From the total admissions, 90% were elective and 10% unplanned. Mean annual estimated costs over the period were £46 million for elective and £56 million for unplanned admissions. The number of elective admissions increased by 4.5% with costs increasing 1.5% per year; for unplanned admissions, these figures were 4.1% and 9.0%, respectively.
CONCLUSIONS CONCLUSIONS
MM is associated with a significant number of hospital admissions and NHS costs. The majority of the hospital admissions are elective, but the highest burden in terms of costs relates to unplanned admissions, with numbers increasing over time.

Identifiants

pubmed: 31223562
doi: 10.1016/j.jbo.2019.100243
pii: S2212-1374(19)30028-4
pii: 100243
pmc: PMC6579752
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100243

Subventions

Organisme : Medical Research Council
ID : MC_U147585827
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_U147585819
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UP_A620_1014
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12011/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0400491
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_U147585824
Pays : United Kingdom

Références

Eur J Haematol. 2005 Feb;74(2):136-43
pubmed: 15654905
Hematology Am Soc Hematol Educ Program. 2005;:353-9
pubmed: 16304403
Blood. 2008 Mar 1;111(5):2516-20
pubmed: 17975015
Hematol Oncol Clin North Am. 2007 Dec;21(6):1231-46, xi
pubmed: 17996596
Neoplasma. 2008;55(4):350-5
pubmed: 18505348
Oncologist. 2010;15(1):6-25
pubmed: 20086168
J Natl Compr Canc Netw. 2010 Feb;8 Suppl 1:S4-S12
pubmed: 20141673
Br J Cancer. 2016 May 24;114(11):1286-92
pubmed: 27070711
Leukemia. 2017 Sep;31(9):1915-1921
pubmed: 28008176
Eur J Haematol. 2017 Aug;99(2):119-132
pubmed: 28306169
Int J Epidemiol. 2017 Aug 1;46(4):1093-1093i
pubmed: 28338941
Eur Urol Focus. 2018 Jul;4(4):586-590
pubmed: 28753845
Leuk Lymphoma. 2018 Apr;59(4):941-949
pubmed: 28805105
Int J Epidemiol. 2017 Dec 1;46(6):1786-1796
pubmed: 29025095
Int J Cancer. 2018 Aug 15;143(4):773-781
pubmed: 29516512
JAMA Oncol. 2018 Sep 1;4(9):1221-1227
pubmed: 29800065

Auteurs

Spyros Kolovos (S)

Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Old Rd, Oxford OX3 7LD, UK.

Guido Nador (G)

Oxford University Hospitals NHS Trust, Oxford, UK.

Bhuvan Kishore (B)

Heart of England NHS Foundation Trust, Birmingham, UK.

Matthew Streetly (M)

Guy's and St. Thomas' NHS Foundation Trust and King's College London, London, UK.

Neil K Rabin (NK)

Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.

Andrew D Chantry (AD)

Department of Oncology and Metabolism, Medical School, University of Sheffield, Sheffield, UK.
Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital, Sheffield, UK.

Kwee Yong (K)

Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
UCL Cancer Institute, London, UK.

John Ashcroft (J)

Department of Haematology, Mid Yorkshire NHS Trust, Wakefield, UK.

Stella Bowcock (S)

King's College Hospital NHS Trust, London, UK.

Mark T Drayson (MT)

Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.

Karthik Ramasamy (K)

Oxford University Hospitals NHS Trust, Oxford, UK.

Daniel Prieto-Alhambra (D)

Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
Grup de Recerca en Malalties Prevalents de l'Aparell Locomotor Research Group and CIBERFes, University Institute for Primary CareResearch Jordi Gol, Universitat Autonoma de Barcelona and Instituto de Salud Carlos III, Barcelona, Spain.

Cyrus Cooper (C)

MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK.
NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK.
NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.

M Kassim Javaid (MK)

Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Old Rd, Oxford OX3 7LD, UK.

Rafael Pinedo-Villanueva (R)

Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Old Rd, Oxford OX3 7LD, UK.

Classifications MeSH